New-onset diabetes after transplantation: 2003 international consensus GUIDELINES1

…, BL Kasiske, B Kiberd, A Krentz, C Legendre… - …, 2003 - journals.lww.com
Diabetes mellitus is 1one of the most common chronic diseases in the world, with an estimated
worldwide prevalence of over 176 million in 2000. Furthermore, the prevalence of the …

New insights into postrenal transplant hemolytic uremic syndrome

…, C Loirat, V Frémeaux-Bacchi, C Legendre - Nature Reviews …, 2011 - nature.com
… CFH, which is devoid of the endothelium-binding C-terminus, maintain regulation of plasma
levels of C3 … mutations associated with HUS are located within the C-terminal region of CFH. …

Factors influencing long‐term outcome after kidney transplantation

C Legendre, G Canaud, F Martinez - Transplant international, 2014 - Wiley Online Library
Many factors influence the long‐term outcome of kidney transplantation, which is defined
very schematically by patient death or renal dysfunction leading to graft loss. The most …

[HTML][HTML] Terminal complement inhibitor eculizumab in atypical hemolytic–uremic syndrome

CM Legendre, C Licht, P Muus… - … England Journal of …, 2013 - Mass Medical Soc
Background Atypical hemolytic–uremic syndrome is a genetic, life-threatening, chronic disease
of complement-mediated thrombotic microangiopathy. Plasma exchange or infusion may …

Banff'09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups

…, J Gloor, D Glotz, E Kraus, C Legendre… - American journal of …, 2010 - Wiley Online Library
The 10th Banff Conference on Allograft Pathology was held in Banff, Canada from August 9
to 14, 2009. A total of 263 transplant clinicians, pathologists, surgeons, immunologists and …

[HTML][HTML] Complement-binding anti-HLA antibodies and kidney-allograft survival

…, JP Empana, M Delahousse, C Legendre… - … England Journal of …, 2013 - Mass Medical Soc
Background Anti-HLA antibodies hamper successful transplantation, and activation of the
complement cascade is involved in antibody-mediated rejection. We investigated whether the …

[HTML][HTML] The Banff 2015 kidney meeting report: current challenges in rejection classification and prospects for adopting molecular pathology

…, ES Kraus, C Lefaucheur, C Legendre… - American journal of …, 2017 - Elsevier
The XIII Banff meeting, held in conjunction the Canadian Society of Transplantation in
Vancouver, Canada, reviewed the clinical impact of updates of C4d-negative antibody-mediated …

[HTML][HTML] Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation

D Lowance, HH Neumayer, CM Legendre… - … England Journal of …, 1999 - Mass Medical Soc
Background Cytomegalovirus (CMV) disease is a major complication of organ transplantation.
We hypothesized that prophylactic treatment with valacyclovir would reduce the risk of …

Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients

ML Cittanova, I Leblanc, CH Legendre, C Mouquet… - The Lancet, 1996 - thelancet.com
Background Hydroxyethylstarch used as a plasma-volume expander in brain-dead kidney
donors has been suggested to induce osmotic-nephrosis-like lesions. We have studied its …

Optimization of initial tacrolimus dose using pharmacogenetic testing

…, JF Subra, P Beaune, C Legendre - Clinical …, 2010 - Wiley Online Library
… The primary end point was the proportion of patients within the targeted CC 0 . In the group
receiving the adapted dose, a higher proportion of patients had values within the targeted C